{"gene":"ADCY5","run_date":"2026-06-09T22:02:41","timeline":{"discoveries":[{"year":2024,"finding":"Cryo-EM structure of AC5 in complex with Gβγ revealed that Gβγ binds to a coiled-coil domain linking the AC5 transmembrane region to its catalytic core and to the C1b regulatory hub. Gain-of-function mutations associated with familial dyskinesia are located at the AC5–Gβγ interface and show reduced conditional activation by Gβγ. A dimeric form of AC5 was also observed, and the proposed mechanism is that Gβγ either prevents AC5 dimerization or allosterically modulates the coiled-coil domain to regulate the catalytic core.","method":"Cryo-electron microscopy structure determination; cell-based and pulldown assays confirming Gβγ interaction; functional characterization of dyskinesia-associated gain-of-function mutants","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structure with orthogonal cell-based and biochemical validation of the Gβγ interaction, plus mutagenesis of disease-associated residues in a single rigorous study","pmids":["38589608"],"is_preprint":false},{"year":2014,"finding":"Missense mutations in ADCY5 (p.R418W, inherited de novo; p.A726T, inherited) cause a statistically significant increase in β-adrenergic receptor agonist-stimulated intracellular cAMP accumulation compared with wild-type protein, establishing these as gain-of-function mutations that increase adenylyl cyclase activity.","method":"Intracellular cAMP accumulation assay under stimulatory and inhibitory conditions in cells expressing wild-type vs. mutant ADCY5","journal":"Annals of neurology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct enzymatic activity assay with multiple mutants; finding independently replicated in subsequent studies","pmids":["24700542"],"is_preprint":false},{"year":2019,"finding":"A panel of ADCY5 gain-of-function variants identified in dyskinesia patients (including R418W, R418Q, A726T, M1029K) exhibit enhanced adenylyl cyclase activity in response to Gαs-mediated stimulation in both cell-based and membrane assays, and show significantly reduced inhibition following D2 dopamine receptor activation. The elevated cAMP response at the membrane translates into increased downstream gene transcription in a neuronal model. The P-site inhibitor SQ22536 preferentially inhibits the overactive gain-of-function mutants.","method":"CRISPR-Cas9-generated adenylyl cyclase-deficient cell lines; membrane and whole-cell cAMP assays; downstream transcriptional reporter assays; pharmacological inhibition","journal":"Biochemical pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted in defined genetic background with multiple orthogonal assays (membrane, cellular, transcriptional) in a single rigorous study","pmids":["30772269"],"is_preprint":false},{"year":2002,"finding":"Both high-affinity and low-affinity Ca²⁺ inhibition of AC5 are exerted at the Mg²⁺-binding sites within the catalytic domain. Mg²⁺ activation decreases the absolute amount of high-affinity Ca²⁺ inhibition without changing its Ki, while decreasing the Ki for low-affinity inhibition, proportional to Mg²⁺ sensitivity of the mutant. Deletion of the N-terminus and C1b domain and chimeras with AC2 confirmed that the catalytic domain alone is responsible for high-affinity inhibition.","method":"Site-directed mutagenesis of the catalytic domain; adenylyl cyclase activity assays with Ca²⁺, Sr²⁺, Ba²⁺; domain deletion and AC5/AC2 chimeric constructs","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution-level in vitro assay with systematic mutagenesis, domain deletions, and chimeras in a single study","pmids":["12065575"],"is_preprint":false},{"year":2010,"finding":"AKAP79/150 directly interacts with AC5 (and AC6 and AC9) through the N-terminal regions of these cyclases. The reciprocal binding surface on AKAP79 was mapped to residues 77–108. Deletion of AKAP79(77–108) abolished AC5–AKAP79 interaction in living cells (FRET). Addition of the AKAP79(77–153) polypeptide uncoupled AC5/6 from the anchoring protein and prevented PKA-mediated inhibition of AC activity in membranes. Loss of AKAP150 in mouse brain resulted in decreased AMPA receptor-associated AC activity, indicating that AKAP79/150 scaffolds AC5 to synaptic AMPA receptors.","method":"Co-immunoprecipitation; intensity- and lifetime-based FRET in living cells; competitive peptide displacement; membrane AC activity assays; AKAP150 knockout mouse brain extracts","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, live-cell FRET, functional membrane assays, and KO mouse biochemistry across multiple orthogonal methods","pmids":["20231277"],"is_preprint":false},{"year":2006,"finding":"AC5 is an essential mediator of mu and delta opioid receptor signaling in the striatum. In AC5 knockout mice, all major behavioral effects of morphine (locomotor activation, analgesia, tolerance, reward, physical dependence/withdrawal) were attenuated. The ability of mu or delta (but not kappa) opioid receptor agonists to suppress striatal adenylyl cyclase activity was absent in AC5⁻/⁻ mice, placing AC5 downstream of mu/delta opioid receptors in striatal cAMP signaling.","method":"AC5 knockout mice; behavioral pharmacology assays; striatal membrane adenylyl cyclase activity assays with selective opioid receptor agonists","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with multiple defined behavioral and biochemical phenotypes, multiple agonists tested, consistent across assays","pmids":["16537460"],"is_preprint":false},{"year":2006,"finding":"Calcium suppresses renin exocytosis from juxtaglomerular cells by inhibiting adenylate cyclases AC5 and AC6, thereby reducing intracellular cAMP. siRNA-mediated knockdown of AC5 and/or AC6 in renin-producing cells prevented calcium-dependent suppression of cAMP levels and renin release. Clamping cAMP with membrane-permeable analogs bypassed the calcium inhibition, confirming that AC5/AC6 are the critical intermediaries of the calcium paradox in renin secretion.","method":"siRNA knockdown of AC5 and AC6 in primary juxtaglomerular cells and As4.1 cell line; cAMP measurement; renin secretion assays; isolated perfused mouse kidney","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — siRNA KD with cAMP and functional secretion readouts, multiple cell types and in vivo perfusion, replicated across conditions","pmids":["17068292"],"is_preprint":false},{"year":2014,"finding":"ADCY5 is indispensable for coupling glucose (but not GLP-1) to insulin secretion in human islets. ADCY5 silencing impaired glucose-induced cAMP increases and blocked glucose metabolism toward ATP at >8 mmol/L glucose. Calcium transient generation and functional connectivity between β-cells were sharply inhibited at all glucose concentrations after ADCY5 knockdown, indicating additional metabolism-independent roles. Calcium rises were unaffected in ADCY5-depleted islets exposed to GLP-1.","method":"siRNA silencing of ADCY5 in human islets; in situ imaging of cAMP and calcium with recombinant probes; glucose metabolism assays; functional connectivity analysis","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean KD with multiple orthogonal readouts (cAMP imaging, Ca²⁺ imaging, ATP metabolism, connectivity) in human islets","pmids":["24740569"],"is_preprint":false},{"year":2017,"finding":"An islet enhancer overlapping rs11708067 regulates ADCY5 expression. The type 2 diabetes risk allele (rs11708067-A) showed reduced H3K27ac marks, lower transcriptional activity in reporter assays, and increased nuclear protein binding. Homozygous deletion of the orthologous enhancer region in 832/13 cells caused a 64% reduction in Adcy5 expression (but not adjacent Sec22a) and a 39% reduction in insulin secretion, establishing this variant as a functional regulatory element for ADCY5 in β-cells.","method":"ChIP-seq; luciferase reporter assays in rodent β-cells; CRISPR-Cas9 enhancer deletion in 832/13 cells; qRT-PCR; insulin secretion assays","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR enhancer deletion with direct gene expression and functional secretion readouts, multiple orthogonal methods","pmids":["28684635"],"is_preprint":false},{"year":2012,"finding":"Heterologous sensitization of AC5 by chronic D2 dopamine receptor activation requires signalosome assembly. Gαs is required for D2-induced sensitization of AC5, but neither Gαs palmitoylation nor Gαs–Gβγ interactions are necessary. Coexpression of βARKct-CD8 or dominant-negative Sar1(H79G) blocked heterologous sensitization, implicating vesicular trafficking and proper signalosome assembly rather than direct Gβγ–AC5 interaction as the mechanism.","method":"Expression of Gαs mutants in Gαs-deficient cells; cAMP sensitization assays; dominant-negative trafficking inhibitors","journal":"Journal of signal transduction","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — cell-based epistasis with defined mutants but single lab, limited replication","pmids":["22523680"],"is_preprint":false},{"year":2019,"finding":"BiFC screening identified two novel AC5 modulators in striatal medium spiny neurons: PP2A catalytic subunit (PPP2CB) and the intracellular trafficking protein NAPA (NSF attachment protein alpha). Knockdown of PPP2CB reduced both acute and sensitized adenylyl cyclase activity, establishing PP2A as a persistent regulator of AC5 activity. NAPA knockdown effects were activity-dependent. Both interactions were validated in D1 and D2 dopamine receptor-expressing MSNs.","method":"Bimolecular fluorescence complementation (BiFC) protein–protein interaction screening; genetic knockdown; cAMP activity assays in neuronal cell lines and primary MSNs from CAMPER mice","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — BiFC interaction screen validated with functional KD assays in multiple cell types; single lab but two orthogonal methods","pmids":["31752385"],"is_preprint":false},{"year":2020,"finding":"AC5 mediates stress-induced suppression of GluA1 protein synthesis and structural plasticity in cerebellar Bergmann glial cells. Acute stress reduced GluA1 protein levels and AMPA receptor-mediated currents in these glia; deletion of adenylyl cyclase 5 prevented GluA1 suppression, placing AC5 downstream of β-adrenergic receptor activation and upstream of CPEB3-dependent translational repression in an adrenergic/adenylyl cyclase/CPEB3/GluA1 pathway.","method":"AC5 knockout mice; β-adrenergic receptor blocker pharmacology; CPEB3 knockout mice; electrophysiology; immunoblotting in cerebellar Bergmann glial cells","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined cellular and molecular phenotype, pathway dissection with pharmacology and multiple KO models","pmids":["32229518"],"is_preprint":false},{"year":2014,"finding":"AC5 overexpression in transgenic mice creates a proarrhythmic substrate by inducing SR Ca²⁺ overload and hyperactivation of ryanodine receptors through CaMKII phosphorylation. AC5Tg myocytes showed higher SR Ca²⁺ content, longer action potential duration, and spontaneous Ca²⁺ waves that induced afterdepolarizations and triggered action potentials. Increased SERCA2a, oxidized CaMKII, and CaMKII-site phosphorylation of RyR were observed, especially after isoproterenol.","method":"AC5 transgenic mice; intracellular Ca²⁺ imaging (fluo-4 AM); action potential recordings; immunoblotting for SERCA2a, CaMKII oxidation, RyR phosphorylation; ROS measurement; in vivo arrhythmia induction","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — transgenic overexpression with multiple orthogonal electrophysiological and biochemical readouts in a single rigorous study","pmids":["25485900"],"is_preprint":false},{"year":2010,"finding":"AC5 knockout mice show increased ethanol consumption and preference and reduced ethanol sensitivity (attenuated hypothermia and sedation/behavioral sleep responses to high-dose ethanol), establishing AC5 as a regulator of alcohol sensitivity and preference in the striatal cAMP pathway.","method":"AC5 knockout mice; two-bottle free-choice ethanol preference; ethanol-induced hypothermia; sedation/loss-of-righting-reflex assay","journal":"Psychopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — clean KO with defined behavioral phenotypes but single lab and no direct biochemical mechanism","pmids":["21193983"],"is_preprint":false},{"year":2022,"finding":"In zebrafish, Adcy3a and Adcy5 double mutants display defects in melanosome dispersion (but not melanoblast differentiation or regeneration). Mechanistically, Adcy3a and Adcy5 regulate melanosome dispersion by activating kinesin-1 while inhibiting cytoplasmic dynein-1, acting through cAMP-PKA signaling downstream of α-MSH/MC1R. In adults, deletion of both cyclases inhibits melanin production by reducing Mitfa and melanin synthesis enzymes (Tyr, Dct, Trp1b).","method":"Zebrafish single and double CRISPR/Cas9 mutants; PKA activator rescue experiments; in vivo imaging of melanosome dispersion; molecular marker analysis of melanin synthesis pathway","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic double-mutant epistasis with functional rescue; ortholog study in zebrafish; single lab","pmids":["36430661"],"is_preprint":false},{"year":2023,"finding":"All three purine derivatives caffeine, theophylline, and istradefylline reduce cAMP production by ADCY5-overexpressing cells. The most pronounced cAMP reduction was observed for the gain-of-function ADCY5 R418W mutant compared to wild-type, demonstrating that these adenosine receptor antagonists preferentially suppress elevated cAMP signaling from the overactive mutant.","method":"ADCY5 wild-type and R418W overexpressing cell lines; cAMP quantification assay following treatment with caffeine, theophylline, and istradefylline","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct cellular cAMP assay with defined mutant vs. wild-type comparison; single lab; mechanism of preferential inhibition not fully resolved","pmids":["36867608"],"is_preprint":false},{"year":2021,"finding":"ADCY5 acts upstream of CPEB3 and GluA1 translation in cerebellar Bergmann glia during stress response, placing it in an adrenergic/AC5/CPEB3/GluA1 signaling axis. AC5 deletion prevented GluA1 suppression and the associated retraction of glial lateral processes, establishing a direct role for AC5 in glial structural plasticity via translational regulation.","method":"AC5 knockout mice; CPEB3 knockout mice; β-adrenergic pharmacology; immunoblotting; electrophysiology","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple genetic KO models with orthogonal molecular, cellular, and electrophysiological readouts","pmids":["32229518"],"is_preprint":false},{"year":2021,"finding":"miR-18a-3p directly targets ADCY5 mRNA as demonstrated by dual luciferase reporter assay and RNA pull-down, suppressing ADCY5 expression and thereby inhibiting osteogenic differentiation of human bone marrow mesenchymal stem cells. Overexpression of ADCY5 increased calcium deposition, ALP activity, and osteoblast protein expression, while miR-18a-3p mimic partially reversed these effects.","method":"Dual luciferase reporter assay; RNA pull-down; ADCY5 overexpression and miR-18a-3p mimic transfection in hBMSCs; ALP activity assay; calcium deposition assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — luciferase reporter and RNA pull-down for miRNA targeting validated with functional osteogenesis assays; single lab","pmids":["33684620"],"is_preprint":false},{"year":2025,"finding":"Artemisinin was shown by molecular docking to directly bind to Adcy5 in rat midbrain. In rescue experiments in vitro, inhibition of Adcy5 abolished artemisinin-generated increases in DA, BH4, and Gch1 expression. In vivo, suppression of Adcy5 aggravated Parkinson's disease manifestations and decreased midbrain DA, BH4, and Gch1 expression, placing Adcy5 upstream of a Gch1-BH4-dopamine biosynthesis axis.","method":"Molecular docking; midbrain proteomics; non-targeted metabolomics; Adcy5 inhibitor rescue experiments in vitro and in vivo in rat Parkinson's disease model","journal":"Genome biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — molecular docking combined with pharmacological inhibition; mechanistic claims rely partly on indirect inhibitor data; single lab, single study","pmids":["40908481"],"is_preprint":false}],"current_model":"ADCY5 (AC5) is a membrane-anchored adenylyl cyclase that converts ATP to cAMP; it is highly expressed in striatal medium spiny neurons and pancreatic β-cells, where gain-of-function mutations enhance Gαs-stimulated cAMP production and reduce D2-receptor-mediated inhibition, while the enzyme is structurally regulated by Gβγ binding to its coiled-coil/C1b domains, is inhibited by Ca²⁺ acting at the Mg²⁺-binding sites of its catalytic core, is scaffolded to AMPA receptors and PKA by AKAP79/150, and is subject to negative feedback phosphorylation by PKA; downstream it mediates glucose-coupled insulin secretion, mu/delta opioid receptor signaling in striatum, adrenergic stress responses in Bergmann glia, melanocyte cAMP-PKA/kinesin-dynein melanosome transport, and alcohol/opioid sensitivity."},"narrative":{"mechanistic_narrative":"ADCY5 (AC5) is a membrane-anchored adenylyl cyclase that converts ATP to cAMP and serves as a signal-integration node coupling G-protein-coupled receptor activation to downstream cAMP-PKA effectors in striatal neurons, pancreatic β-cells, glia, and secretory cells [PMID:30772269, PMID:16537460, PMID:24740569]. Its catalytic core is bidirectionally regulated: Gαs stimulation drives cAMP production while D2 dopamine receptors impose Giα-mediated inhibition, and Ca²⁺ exerts both high- and low-affinity inhibition by acting at the Mg²⁺-binding sites of the catalytic domain [PMID:30772269, PMID:12065575]. Cryo-EM of the AC5–Gβγ complex shows Gβγ binding to a coiled-coil linking the transmembrane region to the catalytic core and to the C1b regulatory hub, where it modulates the catalytic core and AC5 dimerization [PMID:38589608]. Spatial organization and feedback control are provided by AKAP79/150, which binds the AC5 N-terminus to scaffold the cyclase to synaptic AMPA receptors and PKA and to enable PKA-mediated inhibition of AC activity [PMID:20231277]. Gain-of-function missense mutations (R418W, R418Q, A726T, M1029K), several mapping to the Gβγ interface, increase Gαs-stimulated cAMP and reduce D2-mediated inhibition, causing familial dyskinesia [PMID:38589608, PMID:24700542, PMID:30772269]. Physiologically, AC5 is required for glucose-coupled (but not GLP-1-coupled) insulin secretion in human islets and mediates mu/delta opioid receptor signaling and the behavioral effects of morphine in striatum [PMID:16537460, PMID:24740569]. Additional roles include Ca²⁺-dependent suppression of renin secretion, adrenergic/CPEB3/GluA1-dependent structural plasticity in Bergmann glia, and cAMP-PKA-driven melanosome transport [PMID:17068292, PMID:32229518, PMID:36430661].","teleology":[{"year":2002,"claim":"Established where Ca²⁺ inhibits AC5, resolving whether calcium acts on the catalytic core or accessory domains — a key question for understanding feedback control of cAMP output.","evidence":"Site-directed mutagenesis, domain deletions, and AC5/AC2 chimeras with activity assays using divalent cations","pmids":["12065575"],"confidence":"High","gaps":["Does not map the structural basis of the Mg²⁺/Ca²⁺ site at atomic resolution","Physiological Ca²⁺ thresholds in native cells not addressed"]},{"year":2006,"claim":"Placed AC5 downstream of mu/delta but not kappa opioid receptors in striatal cAMP signaling, defining its role in the behavioral pharmacology of morphine.","evidence":"AC5 knockout mice with behavioral pharmacology and striatal membrane adenylyl cyclase assays using selective agonists","pmids":["16537460"],"confidence":"High","gaps":["Does not resolve which downstream effectors transmit the cAMP signal to behavior","Striatal cell-type specificity not dissected"]},{"year":2006,"claim":"Identified AC5 (with AC6) as the calcium-sensitive intermediary explaining the renin secretion calcium paradox in juxtaglomerular cells.","evidence":"siRNA knockdown of AC5/AC6 in primary and As4.1 cells with cAMP and renin secretion readouts plus perfused kidney","pmids":["17068292"],"confidence":"High","gaps":["Relative contributions of AC5 vs AC6 not separated","Does not establish the calcium sensor upstream of the cyclases"]},{"year":2010,"claim":"Defined AKAP79/150 as the scaffold tethering AC5 to synaptic AMPA receptors and PKA, providing the spatial framework for localized cAMP signaling and PKA feedback inhibition.","evidence":"Reciprocal Co-IP, live-cell FRET, competitive peptide displacement, membrane AC assays, and AKAP150 knockout mouse brain","pmids":["20231277"],"confidence":"High","gaps":["Stoichiometry of the AC5–AKAP–PKA–AMPAR complex unresolved","Whether scaffolding alters basal vs stimulated activity not fully separated"]},{"year":2010,"claim":"Linked striatal AC5 cAMP signaling to alcohol sensitivity and consumption, extending its behavioral role beyond opioids.","evidence":"AC5 knockout mice with ethanol preference, hypothermia, and sedation assays","pmids":["21193983"],"confidence":"Medium","gaps":["Single lab, no direct biochemical mechanism for ethanol effects","Brain-region and cell-type contributions undefined"]},{"year":2012,"claim":"Clarified that heterologous sensitization of AC5 by chronic D2 activation depends on vesicular trafficking and signalosome assembly rather than direct Gβγ–AC5 contact.","evidence":"Gαs mutants in Gαs-deficient cells, cAMP sensitization assays, and dominant-negative trafficking inhibitors","pmids":["22523680"],"confidence":"Medium","gaps":["Single lab with limited replication","Identity of the trafficking-dependent signalosome components not defined"]},{"year":2014,"claim":"Demonstrated that ADCY5 missense mutations are gain-of-function, increasing β-adrenergic-stimulated cAMP and providing the molecular basis for familial dyskinesia.","evidence":"Intracellular cAMP accumulation assays comparing wild-type and mutant ADCY5 under stimulatory/inhibitory conditions","pmids":["24700542"],"confidence":"High","gaps":["Does not establish the structural mechanism of activation","Neuronal consequences not directly assayed"]},{"year":2014,"claim":"Established ADCY5 as indispensable for coupling glucose specifically to insulin secretion in human islets, with additional metabolism-independent roles in Ca²⁺ signaling and β-cell connectivity.","evidence":"siRNA silencing in human islets with cAMP/Ca²⁺ imaging, glucose metabolism assays, and connectivity analysis","pmids":["24740569"],"confidence":"High","gaps":["Mechanism distinguishing glucose from GLP-1 coupling unresolved","Basis of metabolism-independent Ca²⁺ effects not defined"]},{"year":2014,"claim":"Showed that excess AC5 activity is proarrhythmic in heart by driving SR Ca²⁺ overload and CaMKII-dependent RyR hyperactivation.","evidence":"AC5 transgenic mice with Ca²⁺ imaging, action potential recordings, and biochemistry of SERCA2a/CaMKII/RyR","pmids":["25485900"],"confidence":"High","gaps":["Overexpression model may not reflect endogenous AC5 levels","Direct cAMP-to-CaMKII oxidation link not fully mapped"]},{"year":2017,"claim":"Identified a functional islet enhancer harboring the T2D risk variant rs11708067 that controls ADCY5 expression and insulin secretion, connecting GWAS signal to a regulatory mechanism.","evidence":"ChIP-seq, luciferase reporters, CRISPR enhancer deletion in 832/13 cells, qRT-PCR, and insulin secretion assays","pmids":["28684635"],"confidence":"High","gaps":["Identity of the allele-specific nuclear binding factor not determined","Human β-cell validation in vivo not addressed"]},{"year":2019,"claim":"Expanded the gain-of-function variant panel and showed mutants combine enhanced Gαs stimulation with reduced D2 inhibition, increasing downstream transcription and exhibiting selective P-site inhibitor sensitivity — establishing pharmacological tractability.","evidence":"CRISPR AC-deficient cell lines, membrane and whole-cell cAMP assays, transcriptional reporters, and SQ22536 inhibition","pmids":["30772269"],"confidence":"High","gaps":["In vivo efficacy of P-site inhibitors not tested","Neuronal circuit-level consequences not assessed"]},{"year":2019,"claim":"Identified PP2A (PPP2CB) and NAPA as AC5 modulators in medium spiny neurons, with PP2A acting as a persistent regulator of cyclase activity.","evidence":"BiFC interaction screening with functional knockdown and cAMP assays in neuronal lines and primary MSNs","pmids":["31752385"],"confidence":"Medium","gaps":["Single lab; reciprocal biochemical validation limited","Whether PP2A acts directly on AC5 or on pathway components unresolved"]},{"year":2020,"claim":"Placed AC5 in an adrenergic/AC5/CPEB3/GluA1 axis governing stress-induced suppression of GluA1 translation and structural plasticity in cerebellar Bergmann glia.","evidence":"AC5 and CPEB3 knockout mice with β-adrenergic pharmacology, electrophysiology, and immunoblotting","pmids":["32229518"],"confidence":"High","gaps":["Direct biochemical link from cAMP to CPEB3 not mapped","Generalizability beyond Bergmann glia unknown"]},{"year":2022,"claim":"Demonstrated AC5 (with AC3a) drives melanosome dispersion via cAMP-PKA control of kinesin-1 and dynein-1 downstream of α-MSH/MC1R, linking AC5 to motor-driven organelle transport.","evidence":"Zebrafish single/double CRISPR mutants with PKA rescue, in vivo melanosome imaging, and melanin pathway marker analysis","pmids":["36430661"],"confidence":"Medium","gaps":["Ortholog study in zebrafish; human relevance not confirmed","Direct PKA targets on motor regulation not identified"]},{"year":2024,"claim":"Resolved the structural basis of Gβγ regulation, showing Gβγ engages the coiled-coil and C1b hub and that dyskinesia mutations cluster at this interface with altered conditional activation.","evidence":"Cryo-EM of AC5–Gβγ with cell-based and pulldown validation and functional mutant characterization","pmids":["38589608"],"confidence":"High","gaps":["Functional consequence of the observed AC5 dimer in cells not established","How Gβγ binding integrates with Gαs and Ca²⁺ inputs not fully resolved"]},{"year":2023,"claim":"Showed adenosine receptor antagonists (caffeine, theophylline, istradefylline) preferentially suppress cAMP from the R418W gain-of-function mutant, indicating a candidate therapeutic strategy for ADCY5 dyskinesia.","evidence":"cAMP quantification in wild-type vs R418W ADCY5-overexpressing cells after compound treatment","pmids":["36867608"],"confidence":"Medium","gaps":["Mechanism of preferential inhibition of mutant not resolved","Overexpression system; endogenous and in vivo effects untested"]},{"year":2021,"claim":"Identified miR-18a-3p as a direct repressor of ADCY5 controlling osteogenic differentiation of human bone marrow mesenchymal stem cells.","evidence":"Dual luciferase reporter, RNA pull-down, and ADCY5 overexpression/miRNA mimic functional osteogenesis assays in hBMSCs","pmids":["33684620"],"confidence":"Medium","gaps":["Single lab; in vivo bone phenotype not tested","Downstream cAMP effectors in osteogenesis not defined"]},{"year":2025,"claim":"Proposed Adcy5 as upstream of a Gch1-BH4-dopamine biosynthesis axis mediating artemisinin protection in a Parkinson's disease model.","evidence":"Molecular docking, midbrain proteomics/metabolomics, and Adcy5 inhibitor rescue experiments in rat PD model","pmids":["40908481"],"confidence":"Low","gaps":["Relies on docking and pharmacological inhibition rather than direct binding/genetic evidence","Single lab, single study","Direct Adcy5-Gch1 mechanistic link not established"]},{"year":null,"claim":"How the distinct regulatory inputs to AC5 — Gαs stimulation, Giα/D2 inhibition, Gβγ allostery, Ca²⁺ inhibition, and PKA feedback — are integrated structurally and dynamically at the catalytic core in native cells remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No integrated structural model combining Gαs, Gβγ, and Ca²⁺ inputs","Cell-type-specific signalosome composition incompletely defined","Functional role of AC5 dimerization in vivo unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0009975","term_label":"cyclase activity","supporting_discovery_ids":[0,1,2,3]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[1,2,3]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[2,5]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,3,4]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,2,5]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[5,10,11]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[7]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1,2,8]}],"complexes":[],"partners":["GNB1","GNG2","AKAP5","PPP2CB","NAPA"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O95622","full_name":"Adenylate cyclase type 5","aliases":["ATP pyrophosphate-lyase 5","Adenylate cyclase type V","Adenylyl cyclase 5","AC5"],"length_aa":1261,"mass_kda":138.9,"function":"Catalyzes the formation of the signaling molecule cAMP in response to G-protein signaling (PubMed:15385642, PubMed:24700542, PubMed:26206488). Mediates signaling downstream of ADRB1 (PubMed:24700542). Regulates the increase of free cytosolic Ca(2+) in response to increased blood glucose levels and contributes to the regulation of Ca(2+)-dependent insulin secretion (PubMed:24740569)","subcellular_location":"Cell membrane; Cell projection, cilium","url":"https://www.uniprot.org/uniprotkb/O95622/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ADCY5","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ADCY5","total_profiled":1310},"omim":[{"mim_id":"620638","title":"POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 4; KCTD4","url":"https://www.omim.org/entry/620638"},{"mim_id":"619651","title":"NEURODEVELOPMENTAL DISORDER WITH HYPERKINETIC MOVEMENTS AND DYSKINESIA; NEDHYD","url":"https://www.omim.org/entry/619651"},{"mim_id":"619647","title":"DYSKINESIA WITH OROFACIAL INVOLVEMENT, AUTOSOMAL RECESSIVE; DSKOR","url":"https://www.omim.org/entry/619647"},{"mim_id":"615192","title":"BIRTH WEIGHT QUANTITATIVE TRAIT LOCUS 4; BWQTL4","url":"https://www.omim.org/entry/615192"},{"mim_id":"613460","title":"FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 6; FGQTL6","url":"https://www.omim.org/entry/613460"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Nuclear bodies","reliability":"Additional"},{"location":"Primary cilium","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":74.2},{"tissue":"heart muscle","ntpm":99.3}],"url":"https://www.proteinatlas.org/search/ADCY5"},"hgnc":{"alias_symbol":["AC5"],"prev_symbol":[]},"alphafold":{"accession":"O95622","domains":[{"cath_id":"3.30.70.1230","chopping":"461-654","consensus_level":"high","plddt":85.4234,"start":461,"end":654},{"cath_id":"-","chopping":"764-856","consensus_level":"medium","plddt":87.6925,"start":764,"end":856},{"cath_id":"3.30.70.1230","chopping":"1049-1255","consensus_level":"high","plddt":86.1136,"start":1049,"end":1255}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O95622","model_url":"https://alphafold.ebi.ac.uk/files/AF-O95622-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O95622-F1-predicted_aligned_error_v6.png","plddt_mean":73.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ADCY5","jax_strain_url":"https://www.jax.org/strain/search?query=ADCY5"},"sequence":{"accession":"O95622","fasta_url":"https://rest.uniprot.org/uniprotkb/O95622.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O95622/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O95622"}},"corpus_meta":[{"pmid":"24740569","id":"PMC_24740569","title":"ADCY5 couples glucose to insulin secretion in human islets.","date":"2014","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/24740569","citation_count":122,"is_preprint":false},{"pmid":"27061943","id":"PMC_27061943","title":"Phenotypic insights into ADCY5-associated disease.","date":"2016","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/27061943","citation_count":105,"is_preprint":false},{"pmid":"26537056","id":"PMC_26537056","title":"ADCY5-related dyskinesia: Broader spectrum and genotype-phenotype correlations.","date":"2015","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26537056","citation_count":102,"is_preprint":false},{"pmid":"24700542","id":"PMC_24700542","title":"Gain-of-function ADCY5 mutations in familial dyskinesia with facial myokymia.","date":"2014","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24700542","citation_count":101,"is_preprint":false},{"pmid":"20231277","id":"PMC_20231277","title":"AKAP79 interacts with multiple adenylyl cyclase (AC) isoforms and scaffolds AC5 and -6 to alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptors.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20231277","citation_count":95,"is_preprint":false},{"pmid":"16537460","id":"PMC_16537460","title":"Adenylyl cyclase type 5 (AC5) is an essential mediator of morphine action.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16537460","citation_count":94,"is_preprint":false},{"pmid":"26010321","id":"PMC_26010321","title":"The AC5 protein encoded by Mungbean yellow mosaic India virus is a pathogenicity determinant that suppresses RNA silencing-based antiviral defenses.","date":"2015","source":"The New phytologist","url":"https://pubmed.ncbi.nlm.nih.gov/26010321","citation_count":80,"is_preprint":false},{"pmid":"22080014","id":"PMC_22080014","title":"The effect of including Lactobacillus reuteri KUB-AC5 during post-hatch feeding on the growth and ileum microbiota of broiler chickens.","date":"2011","source":"Poultry science","url":"https://pubmed.ncbi.nlm.nih.gov/22080014","citation_count":72,"is_preprint":false},{"pmid":"26085604","id":"PMC_26085604","title":"ADCY5 mutations are another cause of benign hereditary chorea.","date":"2015","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26085604","citation_count":71,"is_preprint":false},{"pmid":"28511835","id":"PMC_28511835","title":"ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients.","date":"2017","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/28511835","citation_count":66,"is_preprint":false},{"pmid":"17068292","id":"PMC_17068292","title":"The calcium paradoxon of renin release: calcium suppresses renin exocytosis by inhibition of calcium-dependent adenylate cyclases AC5 and AC6.","date":"2006","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/17068292","citation_count":65,"is_preprint":false},{"pmid":"25545163","id":"PMC_25545163","title":"A de novo ADCY5 mutation causes early-onset autosomal dominant chorea and dystonia.","date":"2014","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/25545163","citation_count":64,"is_preprint":false},{"pmid":"28684635","id":"PMC_28684635","title":"A Type 2 Diabetes-Associated Functional Regulatory Variant in a Pancreatic Islet Enhancer at the ADCY5 Locus.","date":"2017","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/28684635","citation_count":51,"is_preprint":false},{"pmid":"33934385","id":"PMC_33934385","title":"An Update on the Phenotype, Genotype and Neurobiology of ADCY5-Related Disease.","date":"2021","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/33934385","citation_count":46,"is_preprint":false},{"pmid":"35384065","id":"PMC_35384065","title":"Efficacy of Caffeine in ADCY5-Related Dyskinesia: A Retrospective Study.","date":"2022","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/35384065","citation_count":42,"is_preprint":false},{"pmid":"31538084","id":"PMC_31538084","title":"ADCY5-Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder.","date":"2019","source":"Movement disorders clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/31538084","citation_count":38,"is_preprint":false},{"pmid":"12065575","id":"PMC_12065575","title":"A critical interplay between Ca2+ inhibition and activation by Mg2+ of AC5 revealed by mutants and chimeric constructs.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12065575","citation_count":38,"is_preprint":false},{"pmid":"31752385","id":"PMC_31752385","title":"Identification of Novel Adenylyl Cyclase 5 (AC5) Signaling Networks in D1 and D2 Medium Spiny Neurons using Bimolecular Fluorescence Complementation Screening.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31752385","citation_count":38,"is_preprint":false},{"pmid":"27052971","id":"PMC_27052971","title":"Treatment of ADCY5-Associated Dystonia, Chorea, and Hyperkinetic Disorders With Deep Brain Stimulation: A Multicenter Case Series.","date":"2016","source":"Journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27052971","citation_count":38,"is_preprint":false},{"pmid":"30772269","id":"PMC_30772269","title":"Functional characterization of AC5 gain-of-function variants: Impact on the molecular basis of ADCY5-related dyskinesia.","date":"2019","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30772269","citation_count":37,"is_preprint":false},{"pmid":"24751013","id":"PMC_24751013","title":"Aluminum carboxymethyl cellulose-rice bran microcapsules: enhancing survival of Lactobacillus reuteri KUB-AC5.","date":"2012","source":"Carbohydrate polymers","url":"https://pubmed.ncbi.nlm.nih.gov/24751013","citation_count":37,"is_preprint":false},{"pmid":"30406695","id":"PMC_30406695","title":"Protective effect of Lactobacillus reuteri KUB-AC5 against Salmonella Enteritidis challenge in chickens.","date":"2018","source":"Beneficial microbes","url":"https://pubmed.ncbi.nlm.nih.gov/30406695","citation_count":34,"is_preprint":false},{"pmid":"28229249","id":"PMC_28229249","title":"ADCY5-related dyskinesia presenting as familial myoclonus-dystonia.","date":"2017","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/28229249","citation_count":31,"is_preprint":false},{"pmid":"30345538","id":"PMC_30345538","title":"PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology.","date":"2018","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/30345538","citation_count":30,"is_preprint":false},{"pmid":"21193983","id":"PMC_21193983","title":"Mice lacking adenylyl cyclase type 5 (AC5) show increased ethanol consumption and reduced ethanol sensitivity.","date":"2010","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21193983","citation_count":26,"is_preprint":false},{"pmid":"30975617","id":"PMC_30975617","title":"Autosomal recessive ADCY5-Related dystonia and myoclonus: Expanding the genetic spectrum of ADCY5-Related movement disorders.","date":"2019","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/30975617","citation_count":25,"is_preprint":false},{"pmid":"37476318","id":"PMC_37476318","title":"Scoping Review on ADCY5-Related Movement Disorders.","date":"2023","source":"Movement disorders clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/37476318","citation_count":24,"is_preprint":false},{"pmid":"32647899","id":"PMC_32647899","title":"Deep brain stimulation reduces (nocturnal) dyskinetic exacerbations in patients with ADCY5 mutation: a case series.","date":"2020","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32647899","citation_count":22,"is_preprint":false},{"pmid":"25485900","id":"PMC_25485900","title":"Overexpression of adenylyl cyclase type 5 (AC5) confers a proarrhythmic substrate to the heart.","date":"2014","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25485900","citation_count":21,"is_preprint":false},{"pmid":"32949694","id":"PMC_32949694","title":"Polymorphic variants of bovine ADCY5 gene identified in GWAS analysis were significantly associated with ovarian morphological related traits.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/32949694","citation_count":19,"is_preprint":false},{"pmid":"16269537","id":"PMC_16269537","title":"Probing the reorganization of the nicotinic acetylcholine receptor during desensitization by time-resolved covalent labeling using [3H]AC5, a photoactivatable agonist.","date":"2005","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16269537","citation_count":18,"is_preprint":false},{"pmid":"38589608","id":"PMC_38589608","title":"Structure of adenylyl cyclase 5 in complex with Gβγ offers insights into ADCY5-related dyskinesia.","date":"2024","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/38589608","citation_count":17,"is_preprint":false},{"pmid":"32229518","id":"PMC_32229518","title":"Emotional Stress Induces Structural Plasticity in Bergmann Glial Cells via an AC5-CPEB3-GluA1 Pathway.","date":"2020","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32229518","citation_count":17,"is_preprint":false},{"pmid":"24712513","id":"PMC_24712513","title":"Enhancement of Lactobacillus reuteri KUB-AC5 survival in broiler gastrointestinal tract by microencapsulation with alginate-chitosan semi-interpenetrating polymer networks.","date":"2014","source":"Journal of applied microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/24712513","citation_count":16,"is_preprint":false},{"pmid":"28442302","id":"PMC_28442302","title":"Facial twitches in ADCY5-associated disease - Myokymia or myoclonus? An electromyography study.","date":"2017","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/28442302","citation_count":15,"is_preprint":false},{"pmid":"37120528","id":"PMC_37120528","title":"Development of high cell density Limosilactobacillus reuteri KUB-AC5 for cell factory using oxidative stress reduction approach.","date":"2023","source":"Microbial cell factories","url":"https://pubmed.ncbi.nlm.nih.gov/37120528","citation_count":14,"is_preprint":false},{"pmid":"29465345","id":"PMC_29465345","title":"The group I alphabaculovirus-specific protein, AC5, is a novel component of the occlusion body but is not associated with ODVs or the PIF complex.","date":"2018","source":"The Journal of general virology","url":"https://pubmed.ncbi.nlm.nih.gov/29465345","citation_count":14,"is_preprint":false},{"pmid":"30172639","id":"PMC_30172639","title":"Depression and psychosis in ADCY5-related dyskinesia-part of the phenotypic spectrum?","date":"2018","source":"Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","url":"https://pubmed.ncbi.nlm.nih.gov/30172639","citation_count":13,"is_preprint":false},{"pmid":"35205160","id":"PMC_35205160","title":"Probing Genome-Scale Model Reveals Metabolic Capability and Essential Nutrients for Growth of Probiotic Limosilactobacillus reuteri KUB-AC5.","date":"2022","source":"Biology","url":"https://pubmed.ncbi.nlm.nih.gov/35205160","citation_count":12,"is_preprint":false},{"pmid":"28873688","id":"PMC_28873688","title":"Combined effects of holy basil essential oil and inlet temperature on lipid peroxidation and survival of Lactobacillus reuteri KUB-AC5 during spray drying.","date":"2017","source":"Food research international (Ottawa, Ont.)","url":"https://pubmed.ncbi.nlm.nih.gov/28873688","citation_count":12,"is_preprint":false},{"pmid":"34440550","id":"PMC_34440550","title":"ADCY5, CAPN10 and JAZF1 Gene Polymorphisms and Placental Expression in Women with Gestational Diabetes.","date":"2021","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34440550","citation_count":11,"is_preprint":false},{"pmid":"33043083","id":"PMC_33043083","title":"Efficacy of Istradefylline for the Treatment of ADCY5-Related Disease.","date":"2020","source":"Movement disorders clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/33043083","citation_count":10,"is_preprint":false},{"pmid":"36060769","id":"PMC_36060769","title":"AC5 protein encoded by squash leaf curl China virus is an RNA silencing suppressor and a virulence determinant.","date":"2022","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/36060769","citation_count":9,"is_preprint":false},{"pmid":"40079709","id":"PMC_40079709","title":"Treatment Efficacy of Theophylline in ADCY5-Related Dyskinesia: A Retrospective Case Series Study.","date":"2025","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/40079709","citation_count":9,"is_preprint":false},{"pmid":"36867608","id":"PMC_36867608","title":"Effects of theophylline on ADCY5 activation-From cellular studies to improved therapeutic options for ADCY5-related dyskinesia patients.","date":"2023","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/36867608","citation_count":9,"is_preprint":false},{"pmid":"33704598","id":"PMC_33704598","title":"Homozygous ADCY5 mutation causes early-onset movement disorder with severe intellectual disability.","date":"2021","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/33704598","citation_count":9,"is_preprint":false},{"pmid":"33919448","id":"PMC_33919448","title":"Effects of Whole-Body Adenylyl Cyclase 5 (Adcy5) Deficiency on Systemic Insulin Sensitivity and Adipose Tissue.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33919448","citation_count":9,"is_preprint":false},{"pmid":"22523680","id":"PMC_22523680","title":"Dopamine D(2) Receptor-Mediated Heterologous Sensitization of AC5 Requires Signalosome Assembly.","date":"2012","source":"Journal of signal transduction","url":"https://pubmed.ncbi.nlm.nih.gov/22523680","citation_count":9,"is_preprint":false},{"pmid":"21712988","id":"PMC_21712988","title":"Absence of birth-weight lowering effect of ADCY5 and near CCNL, but association of impaired glucose-insulin homeostasis with ADCY5 in Asian Indians.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21712988","citation_count":9,"is_preprint":false},{"pmid":"32163478","id":"PMC_32163478","title":"Common genetic variants in ADCY5 and gestational glycemic traits.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/32163478","citation_count":8,"is_preprint":false},{"pmid":"37906571","id":"PMC_37906571","title":"DNA methylation alterations of ADCY5, MICAL2, and PLEKHG2 during the developmental stage of cryptogenic hepatocellular carcinoma.","date":"2023","source":"Hepatology research : the official journal of the Japan Society of Hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/37906571","citation_count":7,"is_preprint":false},{"pmid":"35720494","id":"PMC_35720494","title":"Type 2 diabetes is more closely associated with risk of colorectal cancer based on elevated DNA methylation levels of ADCY5.","date":"2022","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/35720494","citation_count":7,"is_preprint":false},{"pmid":"32416839","id":"PMC_32416839","title":"Antimicrobial peptide presenting potential strain-specific real time polymerase chain reaction assay for detecting the probiotic Lactobacillus reuteri KUB-AC5 in chicken intestine.","date":"2019","source":"Poultry science","url":"https://pubmed.ncbi.nlm.nih.gov/32416839","citation_count":7,"is_preprint":false},{"pmid":"39091675","id":"PMC_39091675","title":"Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study.","date":"2024","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/39091675","citation_count":6,"is_preprint":false},{"pmid":"33684620","id":"PMC_33684620","title":"By inhibiting ADCY5, miR-18a-3p promotes osteoporosis and possibly contributes to spinal fracture.","date":"2021","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/33684620","citation_count":6,"is_preprint":false},{"pmid":"31970214","id":"PMC_31970214","title":"Hyperphosphorylated Tau, Increased Adenylate Cyclase 5 (ADCY5) Immunoreactivity, but No Neuronal Loss in ADCY5-Dyskinesia.","date":"2019","source":"Movement disorders clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/31970214","citation_count":6,"is_preprint":false},{"pmid":"38230756","id":"PMC_38230756","title":"ADCY5-related dyskinesia - case series with literature review.","date":"2024","source":"Neurologia i neurochirurgia polska","url":"https://pubmed.ncbi.nlm.nih.gov/38230756","citation_count":5,"is_preprint":false},{"pmid":"36430661","id":"PMC_36430661","title":"Requirement of Zebrafish Adcy3a and Adcy5 in Melanosome Dispersion and Melanocyte Stripe Formation.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36430661","citation_count":5,"is_preprint":false},{"pmid":"36539102","id":"PMC_36539102","title":"Early-life low-level lead exposure alters anxiety-like behavior, voluntary alcohol consumption and AC5 protein content in adult male and female C57BL/6 J mice.","date":"2022","source":"Neurotoxicology and teratology","url":"https://pubmed.ncbi.nlm.nih.gov/36539102","citation_count":3,"is_preprint":false},{"pmid":"34707932","id":"PMC_34707932","title":"Integrative growth physiology and transcriptome profiling of probiotic Limosilactobacillus reuteri KUB-AC5.","date":"2021","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/34707932","citation_count":3,"is_preprint":false},{"pmid":"39319137","id":"PMC_39319137","title":"ADCY5 act as a putative tumor suppressor in glioblastoma: An integrated analysis.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/39319137","citation_count":2,"is_preprint":false},{"pmid":"40004085","id":"PMC_40004085","title":"ADCY5 Gene Affects Seasonal Reproduction in Dairy Goats by Regulating Ovarian Granulosa Cells Steroid Hormone Synthesis.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40004085","citation_count":2,"is_preprint":false},{"pmid":"36112278","id":"PMC_36112278","title":"ADCY5 gene mutation: a case report.","date":"2022","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/36112278","citation_count":1,"is_preprint":false},{"pmid":"40300124","id":"PMC_40300124","title":"Pearls & Oy-sters: ADCY5-Related Dyskinesia: From a Longstanding Misdiagnosis of Drug-Resistant Epilepsy.","date":"2025","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/40300124","citation_count":1,"is_preprint":false},{"pmid":"32627162","id":"PMC_32627162","title":"[ADCY5-associated dyskinesia in young children: a case report of a family and an updated review].","date":"2020","source":"Revista de neurologia","url":"https://pubmed.ncbi.nlm.nih.gov/32627162","citation_count":1,"is_preprint":false},{"pmid":"26933606","id":"PMC_26933606","title":"ADCY5 Mutations and Benign Hereditary Chorea.","date":"2015","source":"Pediatric neurology briefs","url":"https://pubmed.ncbi.nlm.nih.gov/26933606","citation_count":1,"is_preprint":false},{"pmid":"30754756","id":"PMC_30754756","title":"Accumulation of ζ-carotene in Chlamydomonas reinhardtii under control of the ac5 nuclear gene.","date":"1999","source":"Plant cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30754756","citation_count":1,"is_preprint":false},{"pmid":"38020658","id":"PMC_38020658","title":"Case report: Diagnosis of ADCY5-related dyskinesia explaining the entire phenotype in a patient with atypical citrullinemia type I.","date":"2023","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38020658","citation_count":1,"is_preprint":false},{"pmid":"40908481","id":"PMC_40908481","title":"Artemisinin alleviates Parkinson's disease by targeting Adcy5-Gch1 axis to trigger a cascade generation of BH4 and dopamine in rats.","date":"2025","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/40908481","citation_count":0,"is_preprint":false},{"pmid":"42063207","id":"PMC_42063207","title":"Distinct Brain Drivers and Shared Cerebello-Cortical Input in ADCY5 and SGCE Hyperkinetic Movements.","date":"2026","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/42063207","citation_count":0,"is_preprint":false},{"pmid":"39546632","id":"PMC_39546632","title":"A Single-Arm, Prospective Study of a Proprietary Synthetic Acellular Self-Assembling Peptide Wound Matrix, AC5® Advanced Wound System, for Treatment of Hard-to-Heal Wounds.","date":"2024","source":"Surgical technology international","url":"https://pubmed.ncbi.nlm.nih.gov/39546632","citation_count":0,"is_preprint":false},{"pmid":"41782543","id":"PMC_41782543","title":"[Autosomal dominant dyskinesia associated with the ADCY5 gene].","date":"2026","source":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","url":"https://pubmed.ncbi.nlm.nih.gov/41782543","citation_count":0,"is_preprint":false},{"pmid":"41705003","id":"PMC_41705003","title":"Nocturnal Ballistic Bouts in ADCY5-Related Movement Disorder.","date":"2026","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/41705003","citation_count":0,"is_preprint":false},{"pmid":"39919432","id":"PMC_39919432","title":"Generation of an induced pluripotent stem cell line (UCLi026-A) from a patient with ADCY5-related disease carrying the heterozygous variant c.1253G > A; (p. Arg418Gln).","date":"2025","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/39919432","citation_count":0,"is_preprint":false},{"pmid":"41799247","id":"PMC_41799247","title":"Mixed Movement Disorder Caused by ADCY5 Pathogenic Variant Successfully Treated With Caffeine: A Case From Ukraine.","date":"2026","source":"Case reports in neurological medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41799247","citation_count":0,"is_preprint":false},{"pmid":"42120309","id":"PMC_42120309","title":"Parkinsonism in Childhood, a Clue to Autosomal Recessive ADCY5-Related Movement Disorder?","date":"2026","source":"Movement disorders clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/42120309","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.04.13.648593","title":"Developmental, neuroanatomical and cellular expression of genes causing dystonia","date":"2025-04-18","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.13.648593","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.19.660566","title":"Proteomic Characterization of Spodoptera frugiperda Granulovirus Occlusion Bodies","date":"2025-06-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.19.660566","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.23.24312408","title":"Treatment Efficacy of Theophylline in ADYC5 Dyskinesia: A Retrospective Case Series Study","date":"2024-08-23","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.23.24312408","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.18.619152","title":"Rapid Hippocampal Synaptic Potentiation Induced by Ketamine Metabolite (  <i>2R</i>  ,  <i>6R</i>  )-Hydroxynorketamine Persistently Primes Synaptic Plasticity","date":"2024-10-22","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.18.619152","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.02.24316741","title":"Genetic Diversity and Expanded Phenotypes in Dystonia: Insights from Large-Scale Exome Sequencing","date":"2024-12-05","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.02.24316741","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":41694,"output_tokens":5585,"usd":0.104428,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14450,"output_tokens":5434,"usd":0.10405,"stage2_stop_reason":"end_turn"},"total_usd":0.208478,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM structure of AC5 in complex with Gβγ revealed that Gβγ binds to a coiled-coil domain linking the AC5 transmembrane region to its catalytic core and to the C1b regulatory hub. Gain-of-function mutations associated with familial dyskinesia are located at the AC5–Gβγ interface and show reduced conditional activation by Gβγ. A dimeric form of AC5 was also observed, and the proposed mechanism is that Gβγ either prevents AC5 dimerization or allosterically modulates the coiled-coil domain to regulate the catalytic core.\",\n      \"method\": \"Cryo-electron microscopy structure determination; cell-based and pulldown assays confirming Gβγ interaction; functional characterization of dyskinesia-associated gain-of-function mutants\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structure with orthogonal cell-based and biochemical validation of the Gβγ interaction, plus mutagenesis of disease-associated residues in a single rigorous study\",\n      \"pmids\": [\"38589608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Missense mutations in ADCY5 (p.R418W, inherited de novo; p.A726T, inherited) cause a statistically significant increase in β-adrenergic receptor agonist-stimulated intracellular cAMP accumulation compared with wild-type protein, establishing these as gain-of-function mutations that increase adenylyl cyclase activity.\",\n      \"method\": \"Intracellular cAMP accumulation assay under stimulatory and inhibitory conditions in cells expressing wild-type vs. mutant ADCY5\",\n      \"journal\": \"Annals of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct enzymatic activity assay with multiple mutants; finding independently replicated in subsequent studies\",\n      \"pmids\": [\"24700542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A panel of ADCY5 gain-of-function variants identified in dyskinesia patients (including R418W, R418Q, A726T, M1029K) exhibit enhanced adenylyl cyclase activity in response to Gαs-mediated stimulation in both cell-based and membrane assays, and show significantly reduced inhibition following D2 dopamine receptor activation. The elevated cAMP response at the membrane translates into increased downstream gene transcription in a neuronal model. The P-site inhibitor SQ22536 preferentially inhibits the overactive gain-of-function mutants.\",\n      \"method\": \"CRISPR-Cas9-generated adenylyl cyclase-deficient cell lines; membrane and whole-cell cAMP assays; downstream transcriptional reporter assays; pharmacological inhibition\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted in defined genetic background with multiple orthogonal assays (membrane, cellular, transcriptional) in a single rigorous study\",\n      \"pmids\": [\"30772269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Both high-affinity and low-affinity Ca²⁺ inhibition of AC5 are exerted at the Mg²⁺-binding sites within the catalytic domain. Mg²⁺ activation decreases the absolute amount of high-affinity Ca²⁺ inhibition without changing its Ki, while decreasing the Ki for low-affinity inhibition, proportional to Mg²⁺ sensitivity of the mutant. Deletion of the N-terminus and C1b domain and chimeras with AC2 confirmed that the catalytic domain alone is responsible for high-affinity inhibition.\",\n      \"method\": \"Site-directed mutagenesis of the catalytic domain; adenylyl cyclase activity assays with Ca²⁺, Sr²⁺, Ba²⁺; domain deletion and AC5/AC2 chimeric constructs\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution-level in vitro assay with systematic mutagenesis, domain deletions, and chimeras in a single study\",\n      \"pmids\": [\"12065575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"AKAP79/150 directly interacts with AC5 (and AC6 and AC9) through the N-terminal regions of these cyclases. The reciprocal binding surface on AKAP79 was mapped to residues 77–108. Deletion of AKAP79(77–108) abolished AC5–AKAP79 interaction in living cells (FRET). Addition of the AKAP79(77–153) polypeptide uncoupled AC5/6 from the anchoring protein and prevented PKA-mediated inhibition of AC activity in membranes. Loss of AKAP150 in mouse brain resulted in decreased AMPA receptor-associated AC activity, indicating that AKAP79/150 scaffolds AC5 to synaptic AMPA receptors.\",\n      \"method\": \"Co-immunoprecipitation; intensity- and lifetime-based FRET in living cells; competitive peptide displacement; membrane AC activity assays; AKAP150 knockout mouse brain extracts\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, live-cell FRET, functional membrane assays, and KO mouse biochemistry across multiple orthogonal methods\",\n      \"pmids\": [\"20231277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"AC5 is an essential mediator of mu and delta opioid receptor signaling in the striatum. In AC5 knockout mice, all major behavioral effects of morphine (locomotor activation, analgesia, tolerance, reward, physical dependence/withdrawal) were attenuated. The ability of mu or delta (but not kappa) opioid receptor agonists to suppress striatal adenylyl cyclase activity was absent in AC5⁻/⁻ mice, placing AC5 downstream of mu/delta opioid receptors in striatal cAMP signaling.\",\n      \"method\": \"AC5 knockout mice; behavioral pharmacology assays; striatal membrane adenylyl cyclase activity assays with selective opioid receptor agonists\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with multiple defined behavioral and biochemical phenotypes, multiple agonists tested, consistent across assays\",\n      \"pmids\": [\"16537460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Calcium suppresses renin exocytosis from juxtaglomerular cells by inhibiting adenylate cyclases AC5 and AC6, thereby reducing intracellular cAMP. siRNA-mediated knockdown of AC5 and/or AC6 in renin-producing cells prevented calcium-dependent suppression of cAMP levels and renin release. Clamping cAMP with membrane-permeable analogs bypassed the calcium inhibition, confirming that AC5/AC6 are the critical intermediaries of the calcium paradox in renin secretion.\",\n      \"method\": \"siRNA knockdown of AC5 and AC6 in primary juxtaglomerular cells and As4.1 cell line; cAMP measurement; renin secretion assays; isolated perfused mouse kidney\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — siRNA KD with cAMP and functional secretion readouts, multiple cell types and in vivo perfusion, replicated across conditions\",\n      \"pmids\": [\"17068292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ADCY5 is indispensable for coupling glucose (but not GLP-1) to insulin secretion in human islets. ADCY5 silencing impaired glucose-induced cAMP increases and blocked glucose metabolism toward ATP at >8 mmol/L glucose. Calcium transient generation and functional connectivity between β-cells were sharply inhibited at all glucose concentrations after ADCY5 knockdown, indicating additional metabolism-independent roles. Calcium rises were unaffected in ADCY5-depleted islets exposed to GLP-1.\",\n      \"method\": \"siRNA silencing of ADCY5 in human islets; in situ imaging of cAMP and calcium with recombinant probes; glucose metabolism assays; functional connectivity analysis\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KD with multiple orthogonal readouts (cAMP imaging, Ca²⁺ imaging, ATP metabolism, connectivity) in human islets\",\n      \"pmids\": [\"24740569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"An islet enhancer overlapping rs11708067 regulates ADCY5 expression. The type 2 diabetes risk allele (rs11708067-A) showed reduced H3K27ac marks, lower transcriptional activity in reporter assays, and increased nuclear protein binding. Homozygous deletion of the orthologous enhancer region in 832/13 cells caused a 64% reduction in Adcy5 expression (but not adjacent Sec22a) and a 39% reduction in insulin secretion, establishing this variant as a functional regulatory element for ADCY5 in β-cells.\",\n      \"method\": \"ChIP-seq; luciferase reporter assays in rodent β-cells; CRISPR-Cas9 enhancer deletion in 832/13 cells; qRT-PCR; insulin secretion assays\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR enhancer deletion with direct gene expression and functional secretion readouts, multiple orthogonal methods\",\n      \"pmids\": [\"28684635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Heterologous sensitization of AC5 by chronic D2 dopamine receptor activation requires signalosome assembly. Gαs is required for D2-induced sensitization of AC5, but neither Gαs palmitoylation nor Gαs–Gβγ interactions are necessary. Coexpression of βARKct-CD8 or dominant-negative Sar1(H79G) blocked heterologous sensitization, implicating vesicular trafficking and proper signalosome assembly rather than direct Gβγ–AC5 interaction as the mechanism.\",\n      \"method\": \"Expression of Gαs mutants in Gαs-deficient cells; cAMP sensitization assays; dominant-negative trafficking inhibitors\",\n      \"journal\": \"Journal of signal transduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — cell-based epistasis with defined mutants but single lab, limited replication\",\n      \"pmids\": [\"22523680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BiFC screening identified two novel AC5 modulators in striatal medium spiny neurons: PP2A catalytic subunit (PPP2CB) and the intracellular trafficking protein NAPA (NSF attachment protein alpha). Knockdown of PPP2CB reduced both acute and sensitized adenylyl cyclase activity, establishing PP2A as a persistent regulator of AC5 activity. NAPA knockdown effects were activity-dependent. Both interactions were validated in D1 and D2 dopamine receptor-expressing MSNs.\",\n      \"method\": \"Bimolecular fluorescence complementation (BiFC) protein–protein interaction screening; genetic knockdown; cAMP activity assays in neuronal cell lines and primary MSNs from CAMPER mice\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — BiFC interaction screen validated with functional KD assays in multiple cell types; single lab but two orthogonal methods\",\n      \"pmids\": [\"31752385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"AC5 mediates stress-induced suppression of GluA1 protein synthesis and structural plasticity in cerebellar Bergmann glial cells. Acute stress reduced GluA1 protein levels and AMPA receptor-mediated currents in these glia; deletion of adenylyl cyclase 5 prevented GluA1 suppression, placing AC5 downstream of β-adrenergic receptor activation and upstream of CPEB3-dependent translational repression in an adrenergic/adenylyl cyclase/CPEB3/GluA1 pathway.\",\n      \"method\": \"AC5 knockout mice; β-adrenergic receptor blocker pharmacology; CPEB3 knockout mice; electrophysiology; immunoblotting in cerebellar Bergmann glial cells\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined cellular and molecular phenotype, pathway dissection with pharmacology and multiple KO models\",\n      \"pmids\": [\"32229518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"AC5 overexpression in transgenic mice creates a proarrhythmic substrate by inducing SR Ca²⁺ overload and hyperactivation of ryanodine receptors through CaMKII phosphorylation. AC5Tg myocytes showed higher SR Ca²⁺ content, longer action potential duration, and spontaneous Ca²⁺ waves that induced afterdepolarizations and triggered action potentials. Increased SERCA2a, oxidized CaMKII, and CaMKII-site phosphorylation of RyR were observed, especially after isoproterenol.\",\n      \"method\": \"AC5 transgenic mice; intracellular Ca²⁺ imaging (fluo-4 AM); action potential recordings; immunoblotting for SERCA2a, CaMKII oxidation, RyR phosphorylation; ROS measurement; in vivo arrhythmia induction\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic overexpression with multiple orthogonal electrophysiological and biochemical readouts in a single rigorous study\",\n      \"pmids\": [\"25485900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"AC5 knockout mice show increased ethanol consumption and preference and reduced ethanol sensitivity (attenuated hypothermia and sedation/behavioral sleep responses to high-dose ethanol), establishing AC5 as a regulator of alcohol sensitivity and preference in the striatal cAMP pathway.\",\n      \"method\": \"AC5 knockout mice; two-bottle free-choice ethanol preference; ethanol-induced hypothermia; sedation/loss-of-righting-reflex assay\",\n      \"journal\": \"Psychopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — clean KO with defined behavioral phenotypes but single lab and no direct biochemical mechanism\",\n      \"pmids\": [\"21193983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In zebrafish, Adcy3a and Adcy5 double mutants display defects in melanosome dispersion (but not melanoblast differentiation or regeneration). Mechanistically, Adcy3a and Adcy5 regulate melanosome dispersion by activating kinesin-1 while inhibiting cytoplasmic dynein-1, acting through cAMP-PKA signaling downstream of α-MSH/MC1R. In adults, deletion of both cyclases inhibits melanin production by reducing Mitfa and melanin synthesis enzymes (Tyr, Dct, Trp1b).\",\n      \"method\": \"Zebrafish single and double CRISPR/Cas9 mutants; PKA activator rescue experiments; in vivo imaging of melanosome dispersion; molecular marker analysis of melanin synthesis pathway\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic double-mutant epistasis with functional rescue; ortholog study in zebrafish; single lab\",\n      \"pmids\": [\"36430661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"All three purine derivatives caffeine, theophylline, and istradefylline reduce cAMP production by ADCY5-overexpressing cells. The most pronounced cAMP reduction was observed for the gain-of-function ADCY5 R418W mutant compared to wild-type, demonstrating that these adenosine receptor antagonists preferentially suppress elevated cAMP signaling from the overactive mutant.\",\n      \"method\": \"ADCY5 wild-type and R418W overexpressing cell lines; cAMP quantification assay following treatment with caffeine, theophylline, and istradefylline\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct cellular cAMP assay with defined mutant vs. wild-type comparison; single lab; mechanism of preferential inhibition not fully resolved\",\n      \"pmids\": [\"36867608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ADCY5 acts upstream of CPEB3 and GluA1 translation in cerebellar Bergmann glia during stress response, placing it in an adrenergic/AC5/CPEB3/GluA1 signaling axis. AC5 deletion prevented GluA1 suppression and the associated retraction of glial lateral processes, establishing a direct role for AC5 in glial structural plasticity via translational regulation.\",\n      \"method\": \"AC5 knockout mice; CPEB3 knockout mice; β-adrenergic pharmacology; immunoblotting; electrophysiology\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic KO models with orthogonal molecular, cellular, and electrophysiological readouts\",\n      \"pmids\": [\"32229518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"miR-18a-3p directly targets ADCY5 mRNA as demonstrated by dual luciferase reporter assay and RNA pull-down, suppressing ADCY5 expression and thereby inhibiting osteogenic differentiation of human bone marrow mesenchymal stem cells. Overexpression of ADCY5 increased calcium deposition, ALP activity, and osteoblast protein expression, while miR-18a-3p mimic partially reversed these effects.\",\n      \"method\": \"Dual luciferase reporter assay; RNA pull-down; ADCY5 overexpression and miR-18a-3p mimic transfection in hBMSCs; ALP activity assay; calcium deposition assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — luciferase reporter and RNA pull-down for miRNA targeting validated with functional osteogenesis assays; single lab\",\n      \"pmids\": [\"33684620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Artemisinin was shown by molecular docking to directly bind to Adcy5 in rat midbrain. In rescue experiments in vitro, inhibition of Adcy5 abolished artemisinin-generated increases in DA, BH4, and Gch1 expression. In vivo, suppression of Adcy5 aggravated Parkinson's disease manifestations and decreased midbrain DA, BH4, and Gch1 expression, placing Adcy5 upstream of a Gch1-BH4-dopamine biosynthesis axis.\",\n      \"method\": \"Molecular docking; midbrain proteomics; non-targeted metabolomics; Adcy5 inhibitor rescue experiments in vitro and in vivo in rat Parkinson's disease model\",\n      \"journal\": \"Genome biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — molecular docking combined with pharmacological inhibition; mechanistic claims rely partly on indirect inhibitor data; single lab, single study\",\n      \"pmids\": [\"40908481\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ADCY5 (AC5) is a membrane-anchored adenylyl cyclase that converts ATP to cAMP; it is highly expressed in striatal medium spiny neurons and pancreatic β-cells, where gain-of-function mutations enhance Gαs-stimulated cAMP production and reduce D2-receptor-mediated inhibition, while the enzyme is structurally regulated by Gβγ binding to its coiled-coil/C1b domains, is inhibited by Ca²⁺ acting at the Mg²⁺-binding sites of its catalytic core, is scaffolded to AMPA receptors and PKA by AKAP79/150, and is subject to negative feedback phosphorylation by PKA; downstream it mediates glucose-coupled insulin secretion, mu/delta opioid receptor signaling in striatum, adrenergic stress responses in Bergmann glia, melanocyte cAMP-PKA/kinesin-dynein melanosome transport, and alcohol/opioid sensitivity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ADCY5 (AC5) is a membrane-anchored adenylyl cyclase that converts ATP to cAMP and serves as a signal-integration node coupling G-protein-coupled receptor activation to downstream cAMP-PKA effectors in striatal neurons, pancreatic β-cells, glia, and secretory cells [#2, #5, #7]. Its catalytic core is bidirectionally regulated: Gαs stimulation drives cAMP production while D2 dopamine receptors impose Giα-mediated inhibition, and Ca²⁺ exerts both high- and low-affinity inhibition by acting at the Mg²⁺-binding sites of the catalytic domain [#2, #3]. Cryo-EM of the AC5–Gβγ complex shows Gβγ binding to a coiled-coil linking the transmembrane region to the catalytic core and to the C1b regulatory hub, where it modulates the catalytic core and AC5 dimerization [#0]. Spatial organization and feedback control are provided by AKAP79/150, which binds the AC5 N-terminus to scaffold the cyclase to synaptic AMPA receptors and PKA and to enable PKA-mediated inhibition of AC activity [#4]. Gain-of-function missense mutations (R418W, R418Q, A726T, M1029K), several mapping to the Gβγ interface, increase Gαs-stimulated cAMP and reduce D2-mediated inhibition, causing familial dyskinesia [#0, #1, #2]. Physiologically, AC5 is required for glucose-coupled (but not GLP-1-coupled) insulin secretion in human islets and mediates mu/delta opioid receptor signaling and the behavioral effects of morphine in striatum [#5, #7]. Additional roles include Ca²⁺-dependent suppression of renin secretion, adrenergic/CPEB3/GluA1-dependent structural plasticity in Bergmann glia, and cAMP-PKA-driven melanosome transport [#6, #11, #14].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established where Ca²⁺ inhibits AC5, resolving whether calcium acts on the catalytic core or accessory domains — a key question for understanding feedback control of cAMP output.\",\n      \"evidence\": \"Site-directed mutagenesis, domain deletions, and AC5/AC2 chimeras with activity assays using divalent cations\",\n      \"pmids\": [\"12065575\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not map the structural basis of the Mg²⁺/Ca²⁺ site at atomic resolution\", \"Physiological Ca²⁺ thresholds in native cells not addressed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Placed AC5 downstream of mu/delta but not kappa opioid receptors in striatal cAMP signaling, defining its role in the behavioral pharmacology of morphine.\",\n      \"evidence\": \"AC5 knockout mice with behavioral pharmacology and striatal membrane adenylyl cyclase assays using selective agonists\",\n      \"pmids\": [\"16537460\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not resolve which downstream effectors transmit the cAMP signal to behavior\", \"Striatal cell-type specificity not dissected\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified AC5 (with AC6) as the calcium-sensitive intermediary explaining the renin secretion calcium paradox in juxtaglomerular cells.\",\n      \"evidence\": \"siRNA knockdown of AC5/AC6 in primary and As4.1 cells with cAMP and renin secretion readouts plus perfused kidney\",\n      \"pmids\": [\"17068292\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of AC5 vs AC6 not separated\", \"Does not establish the calcium sensor upstream of the cyclases\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined AKAP79/150 as the scaffold tethering AC5 to synaptic AMPA receptors and PKA, providing the spatial framework for localized cAMP signaling and PKA feedback inhibition.\",\n      \"evidence\": \"Reciprocal Co-IP, live-cell FRET, competitive peptide displacement, membrane AC assays, and AKAP150 knockout mouse brain\",\n      \"pmids\": [\"20231277\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the AC5–AKAP–PKA–AMPAR complex unresolved\", \"Whether scaffolding alters basal vs stimulated activity not fully separated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Linked striatal AC5 cAMP signaling to alcohol sensitivity and consumption, extending its behavioral role beyond opioids.\",\n      \"evidence\": \"AC5 knockout mice with ethanol preference, hypothermia, and sedation assays\",\n      \"pmids\": [\"21193983\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, no direct biochemical mechanism for ethanol effects\", \"Brain-region and cell-type contributions undefined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Clarified that heterologous sensitization of AC5 by chronic D2 activation depends on vesicular trafficking and signalosome assembly rather than direct Gβγ–AC5 contact.\",\n      \"evidence\": \"Gαs mutants in Gαs-deficient cells, cAMP sensitization assays, and dominant-negative trafficking inhibitors\",\n      \"pmids\": [\"22523680\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab with limited replication\", \"Identity of the trafficking-dependent signalosome components not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated that ADCY5 missense mutations are gain-of-function, increasing β-adrenergic-stimulated cAMP and providing the molecular basis for familial dyskinesia.\",\n      \"evidence\": \"Intracellular cAMP accumulation assays comparing wild-type and mutant ADCY5 under stimulatory/inhibitory conditions\",\n      \"pmids\": [\"24700542\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not establish the structural mechanism of activation\", \"Neuronal consequences not directly assayed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established ADCY5 as indispensable for coupling glucose specifically to insulin secretion in human islets, with additional metabolism-independent roles in Ca²⁺ signaling and β-cell connectivity.\",\n      \"evidence\": \"siRNA silencing in human islets with cAMP/Ca²⁺ imaging, glucose metabolism assays, and connectivity analysis\",\n      \"pmids\": [\"24740569\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism distinguishing glucose from GLP-1 coupling unresolved\", \"Basis of metabolism-independent Ca²⁺ effects not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed that excess AC5 activity is proarrhythmic in heart by driving SR Ca²⁺ overload and CaMKII-dependent RyR hyperactivation.\",\n      \"evidence\": \"AC5 transgenic mice with Ca²⁺ imaging, action potential recordings, and biochemistry of SERCA2a/CaMKII/RyR\",\n      \"pmids\": [\"25485900\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Overexpression model may not reflect endogenous AC5 levels\", \"Direct cAMP-to-CaMKII oxidation link not fully mapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified a functional islet enhancer harboring the T2D risk variant rs11708067 that controls ADCY5 expression and insulin secretion, connecting GWAS signal to a regulatory mechanism.\",\n      \"evidence\": \"ChIP-seq, luciferase reporters, CRISPR enhancer deletion in 832/13 cells, qRT-PCR, and insulin secretion assays\",\n      \"pmids\": [\"28684635\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the allele-specific nuclear binding factor not determined\", \"Human β-cell validation in vivo not addressed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Expanded the gain-of-function variant panel and showed mutants combine enhanced Gαs stimulation with reduced D2 inhibition, increasing downstream transcription and exhibiting selective P-site inhibitor sensitivity — establishing pharmacological tractability.\",\n      \"evidence\": \"CRISPR AC-deficient cell lines, membrane and whole-cell cAMP assays, transcriptional reporters, and SQ22536 inhibition\",\n      \"pmids\": [\"30772269\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo efficacy of P-site inhibitors not tested\", \"Neuronal circuit-level consequences not assessed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified PP2A (PPP2CB) and NAPA as AC5 modulators in medium spiny neurons, with PP2A acting as a persistent regulator of cyclase activity.\",\n      \"evidence\": \"BiFC interaction screening with functional knockdown and cAMP assays in neuronal lines and primary MSNs\",\n      \"pmids\": [\"31752385\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; reciprocal biochemical validation limited\", \"Whether PP2A acts directly on AC5 or on pathway components unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placed AC5 in an adrenergic/AC5/CPEB3/GluA1 axis governing stress-induced suppression of GluA1 translation and structural plasticity in cerebellar Bergmann glia.\",\n      \"evidence\": \"AC5 and CPEB3 knockout mice with β-adrenergic pharmacology, electrophysiology, and immunoblotting\",\n      \"pmids\": [\"32229518\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical link from cAMP to CPEB3 not mapped\", \"Generalizability beyond Bergmann glia unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated AC5 (with AC3a) drives melanosome dispersion via cAMP-PKA control of kinesin-1 and dynein-1 downstream of α-MSH/MC1R, linking AC5 to motor-driven organelle transport.\",\n      \"evidence\": \"Zebrafish single/double CRISPR mutants with PKA rescue, in vivo melanosome imaging, and melanin pathway marker analysis\",\n      \"pmids\": [\"36430661\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ortholog study in zebrafish; human relevance not confirmed\", \"Direct PKA targets on motor regulation not identified\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Resolved the structural basis of Gβγ regulation, showing Gβγ engages the coiled-coil and C1b hub and that dyskinesia mutations cluster at this interface with altered conditional activation.\",\n      \"evidence\": \"Cryo-EM of AC5–Gβγ with cell-based and pulldown validation and functional mutant characterization\",\n      \"pmids\": [\"38589608\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of the observed AC5 dimer in cells not established\", \"How Gβγ binding integrates with Gαs and Ca²⁺ inputs not fully resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed adenosine receptor antagonists (caffeine, theophylline, istradefylline) preferentially suppress cAMP from the R418W gain-of-function mutant, indicating a candidate therapeutic strategy for ADCY5 dyskinesia.\",\n      \"evidence\": \"cAMP quantification in wild-type vs R418W ADCY5-overexpressing cells after compound treatment\",\n      \"pmids\": [\"36867608\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of preferential inhibition of mutant not resolved\", \"Overexpression system; endogenous and in vivo effects untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified miR-18a-3p as a direct repressor of ADCY5 controlling osteogenic differentiation of human bone marrow mesenchymal stem cells.\",\n      \"evidence\": \"Dual luciferase reporter, RNA pull-down, and ADCY5 overexpression/miRNA mimic functional osteogenesis assays in hBMSCs\",\n      \"pmids\": [\"33684620\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; in vivo bone phenotype not tested\", \"Downstream cAMP effectors in osteogenesis not defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Proposed Adcy5 as upstream of a Gch1-BH4-dopamine biosynthesis axis mediating artemisinin protection in a Parkinson's disease model.\",\n      \"evidence\": \"Molecular docking, midbrain proteomics/metabolomics, and Adcy5 inhibitor rescue experiments in rat PD model\",\n      \"pmids\": [\"40908481\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Relies on docking and pharmacological inhibition rather than direct binding/genetic evidence\", \"Single lab, single study\", \"Direct Adcy5-Gch1 mechanistic link not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the distinct regulatory inputs to AC5 — Gαs stimulation, Giα/D2 inhibition, Gβγ allostery, Ca²⁺ inhibition, and PKA feedback — are integrated structurally and dynamically at the catalytic core in native cells remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No integrated structural model combining Gαs, Gβγ, and Ca²⁺ inputs\", \"Cell-type-specific signalosome composition incompletely defined\", \"Functional role of AC5 dimerization in vivo unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0009975\", \"supporting_discovery_ids\": [0, 1, 2, 3]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [1, 2, 3]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [2, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 3, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 2, 5]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [5, 10, 11]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 2, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"GNB1\", \"GNG2\", \"AKAP5\", \"PPP2CB\", \"NAPA\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}